Table 1.
Gene therapies approved by the SFDA, FDA or EMA
| Product | Indications | Approval | Delivery route | Delivery vector | Mechanism | References |
|---|---|---|---|---|---|---|
| Gendicine | head and neck cancer | 2003 | intratumoral injection | recombinant Adenovirus vector | deliver functional copies of the p53 gene | Peng et al.47 |
| Glybera | familial lipoprotein lipase deficiency | 2012 | intravenous infusion | AAV vector | deliver functional copies of the LPL gene | Gaudet et al.48 |
| Strimvelis | ADA-SCIDa | 2016 | ex vivo/HSCe | gamma-retroviral vector | deliver functional copies of the ADA gene | Cicalese et al.49 |
| Luxturna | LCAb or retinitis pigmentosa | 2017 | subretinal injection | AAV2 | deliver functional copies of the RPE65 gene | Russell et al.51 |
| Zolgensma | spinal muscular atrophy (SMA) | 2019 | intravenous infusion | AAV9 | deliver functional copies of the SMN1 gene | Mendell et al.54 |
| Zynteglo | transfusion-dependent β-thalassemia | 2019 | ex vivo/HSCe | gamma-retroviral vector | deliver functional copies of the β-globin gene | Locatelli et al.55 |
| ROCTAVIAN | hemophilia A | 2019 | intravenous infusion | AAV5 | deliver functional copies of FVIII gene | Ozelo et al.56 |
| Libmeldy | metachromatic leukodystrophy (MLD) | 2020 | intrathecal injection | lentiviral vector | deliver functional copies of the arylsulfatase A gene | Sessa et al.57 |
| ADSTILADRIN | high-grade, BCG-unresponsive NMIBCc | 2022 | intravesical | adenovirus vector | deliver functional copies of the IFNα2b gene | Boorjian et al.58 |
| HEMGENIX | hemophilia B | 2022 | intravenous infusion | AAV5 | deliver functional copies of the factor IX gene | Pipe et al.59 |
| SKYSONA | boys with early, active CALDd | 2022 | ex vivo/HSCe | lentiviral vector | deliver functional copies of the ABCD1 gene | Eichler et al.60 |
| ELEVIDYS | duchenne muscular dystrophy (DMD) | 2023 | intravenous infusion | AAV vector | deliver functional copies of an engineered dystrophin gene | Mendell et al.61 |
| VYJUVEK | dystrophic epidermolysis bullosa | 2023 | tropical | non-replicating Herpes simplex virus | deliver functional copies of the COL7A1 gene | Guide et al.52 |
| CASGEVY | sickle cell diseases | 2024 | ex vivo/HSCe | electroporation | deliver CRISPR/Cas9-sgRNA RNP to disrupt the BCL11A enhancer & restore γ-globin expression | Frangoul et al.62 |
| LYFGENIA | sickle cell diseases | 2024 | ex vivo/HSCe | lentiviral vector | deliver functional copies of the β-globin gene | Kanter et al.63 |
ADA-SCID: severe combined immunodeficiency due to adenosine deaminase deficiency.
LCA: Leber Congenital Amaurosis.
BCG-unresponsive NMIBC: Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).
CALD: cerebral adrenoleukodystrophy.
HSC: hematopoietic stem cell.